Arcus Biosciences stock rises 1.66% after arcusbio announces AVEO Oncology clinical study partnership

Arcus Biosciences stock rises 1.66% after arcusbio announces AVEO Oncology clinical study partnership
Arcus Biosciences up 1.66% today

Arcus Biosciences announced a clinical supply agreement with AVEO Oncology to evaluate casdatifan in combination with a VEGFR tyrosine kinase inhibitor.

Highlights

  • RCUS is in a strong bullish trend across timeframes, trading near the weekly range top after a 9.5% rally.
  • Momentum indicators are decisively bullish, though minor overbought signals and weak ADX suggest potential near-term consolidation.
  • Price is expected to remain between $28.00 and $32.75 next week, with further gains likely unless support at $28.00 breaks.

The companies will conduct the evaluation in a new cohort of the ARC-20 platform study for patients with advanced disease. Arcus Biosciences described casdatifan as an investigational HIF-2α inhibitor.

Bullish trend structure as prices hold above key moving averages

RCUS is trading at $29.97, above the MA-20 ($29.24), MA-50 ($26.21), and MA-200 ($22.73), which signals ongoing bullish structure across short-, medium-, and long-term trends. The Ichimoku Kijun level on D1 sits at $27.52, marking immediate support near current levels; near-term support is at $29.24 (MA-20) and key support at $26.21 (MA-50), with near-term resistance at $31.74 (52-week high, just above) and key resistance at $29.97 (current top of weekly range).

Aggressive upside momentum amid mixed conviction signals and elevated volatility

Momentum signals remain positive. MACD on D1 gives a strong buy, but ADX on D1 is low at 14.91 and neutral, suggesting the trend may lack true conviction. RSI on D1 reads 58, a bullish but not overheated zone. However, Stoch RSI and CCI on D1 are both neutral, while BBP on D1 is overbought with a reading of 1.07, signaling strong buyer dominance. The Awesome Oscillator also confirms the bullish tone. In today's session, RCUS is up 1.66% and trading at the very top of its weekly range following a robust 9.5% rally from a prev_week_close of $27.37, with weekly volatility standing at 15.15%. The move reflects aggressive upside momentum with minor signs of possible exhaustion at these highs.

Further upside favored as positive signals meet resistance near highs

Looking ahead, the expected trading range for the next week is estimated at $28.00 to $32.75, adjusted to fit within a realistic band around the current price and based on typical volatility. This range places RCUS closer to its 52-week high ($31.74) and well above the annual low of $8.84. With all W1 indicators—MA-50, RSI, ADX, and MACD—generating buy signals, the probability of further price appreciation is very high (more than 80%), while a pullback is less likely. Baseline scenario sees price holding between $28.00 and $32.75 as momentum cools near resistance. A bullish scenario could see RCUS breaking above $32.75 towards its yearly high if buyer pressure persists. On the downside, a break below $28.00 may trigger profit-taking and a pullback toward stronger supports at $26.21 and $24.66.

Previously it was reported that Arcus Biosciences maintained a strong bullish trend despite encountering short-term volatility and a technical pullback. As new developments unfold, traders should monitor for shifts in trend strength that could present actionable opportunities in the sessions ahead.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.